Application and Research Progress of 225 Ac in Tumor Targeted Treatment
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240617.007
- VernacularTitle:225Ac在肿瘤靶向治疗中的应用及进展
- Author:
Liqin WANG
1
;
Jiangyan LIU
Author Information
1. 兰州大学第二医院核医学科,甘肃 兰州 730030;兰州大学第二临床医学院,甘肃 兰州 730030
- Keywords:
Actinium-225;
α-emitting radionuclide;
tumor;
targeted α-therapy;
polypeptide;
antibody;
nanocarrier
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2024;45(4):503-510
- CountryChina
- Language:Chinese
-
Abstract:
225Ac has high linear energy transfer,suitable half-life,short particle range,and good coordination abili-ty,making it one of the promising alpha emitters in targeted radioisotope therapy for tumors,and it has significant research value.This article briefly introduces the physical and chemical properties of 225Ac,as well as common chelating agents(prostate-specific membrane antigen,octreotide,nano-carriers,etc.).It reviews the applications of targeted drugs la-beled with 225Ac in tumors,based on peptides or small molecules as targeting agents,monoclonal antibodies or proteins as targeting molecules,and nano-carriers.It also analyzes the value of its application in therapy,summarizes the methods of labeling with 225Ac and the selection of suitable chelating agents,improvements in targeting specificity,and toxicity side ef-fects.Furthermore,it looks forward to the localization of 225Ac production to meet future clinical needs,in order to provide reference for the subsequent development of 225Ac-labeled drugs.
